Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Cytomx Therapeutics INC. (CTMX)

179 + Investors. Track Smart Money conviction in CTMX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +57
Streak
4Q ▲
Buyers last Q
73%

Smart Money Signals — CTMX

Based on 179 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 4 quarters in a row

last 6Q
For 4 consecutive quarters, more hedge funds added CTMX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
179 hedge funds hold CTMX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +180% more funds vs a year ago

fund count last 6Q
+115 new funds entered over the past year (+180% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 73% buying

138 buying51 selling
Last quarter: 138 funds were net buyers (78 opened a brand new position + 60 added to an existing one). Only 51 were sellers (30 trimmed + 21 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+38 vs last Q)

new funds entering per quarter
Funds opening a new CTMX position: 31 → 34 → 40 → 78. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
📌

Mixed — 39% long-term, 46% new

■ 39% conviction (2yr+) ■ 16% medium ■ 46% new
Of the 179 current holders: 69 (39%) held >2 years, 28 held 1–2 years, and 82 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
🚀

Acceleration phase — new buyers rushing in

7 → 31 → 34 → 40 → 78 new funds/Q
New funds entering each quarter: 31 → 34 → 40 → 78. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Veteran-anchored — 51% veterans vs 42% newcomers

■ 51% veterans ■ 7% 1-2yr ■ 42% new
Entry-cohort mix of 190 holders: 97 (51%) are 2+ year veterans, 14 entered 1–2 years ago, and 79 (42%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 42% AUM from top-100 funds

42% from top-100 AUM funds
37 of 177 holders are among the 100 largest funds by AUM, controlling 42% of total institutional value in CTMX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
5.8
out of 10
Moderate Exit Risk
Exit risk score 5.8/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CTMX

In 2026 Q1, 138 hedge funds were net buyers of CTMX (78 opened a new position, 60 added to an existing one), while 51 reduced or exited (30 trimmed, 21 sold completely) — a 73% buyer ratio, indicating clear institutional accumulation. This marks 4 consecutive quarters of net institutional buying — a persistent conviction signal. 42% of total institutional value in CTMX is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +57 funds (more new holders than closures). Total institutional holders: 179.

Hedge Fund Ownership: CTMX

How many hedge funds hold CTMX — quarterly history vs. share price
Quarterly hedge fund ownership of CTMX vs. share price

Market Analysis: CTMX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CTMX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Cytomx Therapeutics INC. (CTMX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much CTMX has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 46d ago
CTMX
-10.4%
XLV
+5.5%

CTMX outperformed XLV by -15.9% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 1d ago
CTMX
+0.0%
XLV
+0.0%

Since the filing became public, CTMX outperformed XLV by +0.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

15 top-rated funds 1 high-conviction
Consensus
5.2
/ 10
breadth
×
Elite
2.3
/ 10
conviction
Hedge Fund Positioning: CTMX
2026 Q2 Stats Unlock in 4 days 179 + Investors

Track Smart Money conviction in CTMX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 179 122 46.72%
13F Shares 198M 145M 36.46%
Total Value $932M $619M 50.39%
New Positions 78 40 +38
Increased Positions 59 38 +21
Closed Positions 21 22 -1
Reduced Positions 26 25 +1
Total Calls 8 6 33.33%
Total Puts 4 2 100.0%
PUT/CALL Ratio 0.5 0.33 Bullish

Statistics: CTMX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

179 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CTMX. Verified SEC 13F-HR filings.

QUARTER:
2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.
Top 25 CTMX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Kynam Capital Management, LP 4.50% 21,703,093 $81.4M
2 Elmind Capital, LP 4.29% 4,550,000 $17.1M
3 Ally Bridge Group (NY) LLC 2.57% 775,000 $2.9M
4 Exome Asset Management LLC 1.06% 460,067 $1.7M
5 Nextech Invest Ltd. 0.79% 4,449,932 $16.7M
6 Schulhoff & Co Inc 0.72% 477,550 $1.8M
7 Eversept Partners, LP 0.69% 3,558,497 $13.3M
8 Verdad Advisers, LP 0.63% 176,407 $662K
9 Perceptive Advisors LLC 0.59% 10,439,185 $39.1M
10 ADAR1 Capital Management, LLC 0.58% 3,365,118 $12.6M
11 Venrock Adviser, LLC 0.57% 4,982,124 $18.7M
12 Sphera Funds Management LTD. 0.43% 879,000 $3.3M
13 Dv Equities, LLC 0.38% 714,000 $2.7M
14 Stonepine Capital Management, LLC 0.36% 205,000 $769K
15 DAFNA Capital Management LLC 0.31% 438,407 $1.6M
16 Velan Capital Investment Management LP 0.27% 120,000 $450K
17 Siren, L.L.C. 0.26% 3,457,711 $13.0M
18 Miller Financial Services LLC 0.26% 85,000 $319K
19 Aspire Growth Partners LLC 0.22% 102,254 $383K
20 Timothy G. Youngquist 2020 Irrevocable Trust 0.16% 51,155 $218K
21 HighVista Strategies LLC 0.15% 169,831 $637K
22 Forefront Analytics, LLC 0.10% 25,033 $94K
23 Virtus Investment Advisers, LLC 0.09% 108,703 $408K
24 Baker BROS. Advisors LP 0.09% 4,975,826 $18.7M
25 PSP Research LLC 0.08% 39,400 $148K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Cytomx Therapeutics INC. (CTMX)

What does the Smart Money Trend signal show for CTMX?

Buying streak — 4 quarters in a row: For 4 consecutive quarters, more hedge funds added CTMX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CTMX?

More buyers than sellers — 73% buying: Last quarter: 138 funds were net buyers (78 opened a brand new position + 60 added to an existing one). Only 51 were sellers (30 trimmed + 21 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for CTMX holders?

Elite ownership — 42% AUM from top-100 funds: 37 of 177 holders are among the 100 largest funds by AUM, controlling 42% of total institutional value in CTMX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held CTMX?

Mixed — 39% long-term, 46% new: Of the 179 current holders: 69 (39%) held >2 years, 28 held 1–2 years, and 82 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Cytomx Therapeutics INC. (CTMX) following the 2026 Q2 hedge fund 13F filings?

As of today, CTMX has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), CTMX has gained -10.4% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →